These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17026787)

  • 1. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
    Montagnani F; Migali C; Fiorentini G
    J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab.
    Ellis LM
    Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M; Roodhart JM; Voest EE
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab: one treatment for all the seasons?
    Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
    J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-angiogenic treatment and colorectal cancer].
    André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of new agents in the treatment of colorectal cancer.
    Ruiz de Erenchun F
    Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
    Ferrara N; Hillan KJ; Gerber HP; Novotny W
    Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bevacizumab].
    Taéron C
    Rev Infirm; 2009; (147):46-8. PubMed ID: 19317091
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body fatness and bevacizumab-based therapy in metastatic colorectal cancer.
    Renehan AG
    Gut; 2010 Mar; 59(3):289-90. PubMed ID: 20207633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.